Bayer Thrombosis drug Asundexian shows positive study result
Asundexian is a so-called factor 11a inhibitor and was being compared to a drug sold under the brand name Eliquis by Pfizer and Bristol-Myers Squibb Co.
New Delhi: Bayer AG said a new thrombosis prevention drug showed positive results in a clinical study designed to determine its safety and optimal dosing.
The company's investigational treatment asundexian demonstrated a 67% reduction in ISTH major and clinically relevant non-major bleeding in patients with atrial fibrillation at risk of stroke, Bayer said Sunday.
Asundexian is a so-called factor 11a inhibitor and was being compared to a drug sold under the brand name Eliquis by Pfizer Inc. and Bristol-Myers Squibb Co.
Bayer is seeking to turn asundexian into a new treatment option in thrombosis prevention to help reignite growth in the pharma business as its blockbusters -- the eye-care treatment Eylea and the blood-thinner Xarelto -- approach the end of their patent protection periods. Bayer is trying to offset the expected sales slowdown by pivoting to cutting-edge medicines.
Read also: Bayer applies in EU for extension of Indication to Finerenone
Bayer shares hit a 52-week high at 65.10 euros on Monday, a 3.3% increase from the previous close.
Chief Executive Officer Werner Baumann has faced investor discontent since the controversial decision to buy Monsanto for $63 billion, which brought U.S. litigation claiming the company's weedkiller Roundup causes cancer. Bayer denies the link but has pledged to spend as much as $16 billion to try to move on. Still, long-time investor Temasek Holdings Pte is pushing for Baumann's ouster, Bloomberg has reported.
The trial of asundexian was designed as a "dose-finding phase 2" study and "not powered to discern or test differences in the rates of thrombotic events," Bayer said in a statement.
Read also: Bayer gets nod for Kerendia to treat type 2 diabetes, CKD in Japan
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.